SCHEMBL2319935

SCHEMBL2319935

CC(C)(O)c1ccc(-n2cnc(-c3c(-c4ccc(F)cc4)noc3C(F)(F)F)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.44
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
MCHR1 Q99705 2/20 0.36
CHRNB2 P17787 1/20 0.36
HTR1B P28222 1/20 0.36
SLC6A4 P31645 1/20 0.36
CHRNA4 P43681 1/20 0.36
UGCG Q16739 1/20 0.36
FFAR4 Q5NUL3 2/20 0.35
GABRA5 P31644 5/20 0.35
LMNA P02545 3/20 0.33
SRC P12931 2/20 0.33
BRAF P15056 2/20 0.33
KDR P35968 2/20 0.33
TP53 P04637 2/20 0.33
MAPT P10636 2/20 0.33
THRB P10828 1/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318109 0.91 PTGS2 (0.46) PTGS2ESR1ESR2MCHR1FFAR4
SCHEMBL2320146 0.87 PTGS2 (0.42) PTGS2ESR1ESR2FFAR4GABRA5
SCHEMBL2317325 0.85 ESR1 (0.48) PTGS2ESR1ESR2FFAR4MAPT
SCHEMBL2319376 0.85 PTGS2 (0.46) PTGS2ESR1ESR2FFAR4GABRA5
SCHEMBL2318424 0.84 PTGS2 (0.44) PTGS2ESR1ESR2FFAR4GABRA5
SCHEMBL2318591 0.83 MAP4K4 (0.50) PTGS2ESR1ESR2FFAR4GABRA5
SCHEMBL2321253 0.83 PTGS2 (0.43) PTGS2ESR1ESR2FFAR4BRAF
SCHEMBL2318362 0.83 GABRA5 (0.52) PTGS2FFAR4GABRA5LMNATP53
SCHEMBL2318205 0.81 MAP4K4 (0.41) PTGS2ESR1ESR2FFAR4LMNA
SCHEMBL3646920 0.81 PTGS2 (0.43) PTGS2ESR1ESR2MCHR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170873-B1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP claimed
US-7851469-B2 Isoxazole-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-14 US claimed
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-01-01 US claimed
EP-2170873-B1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
US-7851469-B2 Isoxazole-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-14 US disclosed
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES GABRA5, GABRA1, GABRA4 PTGS2 2317/4885ESR1 721/4885ESR2 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.